COVID-19 research led by Cambridge
Alongside the excellent care our staff are delivering, we are using our tremendous research capabilities to better understand COVID-19 and its successful management, including development of innovative approaches to testing and treatment.
National studies that we are supporting in Cambridge Hospitals include: PRIEST (Pandemic Respiratory Infection Emergency System Triage) to optimise the triage of people using the emergency care system; RECOVERY (Randomised Evaluation of COvid-19 thERapY), a trial of potential therapies that can be adapted to introduce new treatment arms as potential therapies emerge; and REMAP-CAP (Randomised, Embedded, Multifactorial, Adaptive Platform trial), a trial designed to evaluate a number of treatment options simultaneously and efficiently in critically ill patients.
We have also developed a new research resource in the NIHR COVID-19 BioResource, which allows all patients admitted to Cambridge hospitals to participate in research studies by providing biological samples and health information. The NIHR COVID-19 BioResource will be instrumental in understanding why the virus affects people in such different ways and identifying new treatments.
Our SAMBA (simple amplification-based assay) point of care test is helping us rapidly find out whether patients have COVID-19 and ensure that they receive the right treatment in the right ward of the hospital.
We would like to thank all of the clinical and research staff who have made these remarkable achievements possible in such a short period of time, as well as all of the patients who have participated in our studies and made such a valuable contribution to improving care and treatment for COVID-19.
Page last reviewed: 13 October 2021.
This list will be updated when new studies open to patients on site; please visit here for recruiting studies at CUH led by other hospitals. A list of the national studies already prioritised and approved by NIHR can be found here.
The Post-hospitalisation COVID-19 study (PHOSP-COVID) is a consortium of leading researchers and clinicians from across the UK working together to understand and improve long-term health outcomes for patients who have been in hospital with confirmed or suspected COVID-19.
The NIHR Cambridge Clinical Research Facility is currently recruiting to PHOSP-COVID.
In this study volunteers from the East of England will receive a third ‘booster’ COVID-19 vaccine at the NIHR Cambridge Clinical Research Facility. It will be the first study in the world to provide vital data on the impact of a third dose on patients’ immune responses.
The trial will look at seven different COVID-19 vaccines (including the Oxford/AstraZeneca, Pfizer/BionTech, and Moderna vaccines) as potential boosters, given at least 10 to 12 weeks after a second dose as part of the ongoing vaccination programme. One booster will be provided to each volunteer and could be a different brand to the one they were originally vaccinated with.
Anyone interested in participating can find out more by signing up to the NHS COVID-19 Vaccine Research Registry.
This study is jointly Sponsored by Cambridge University Hospitals and The University of Cambridge.
The acute effects of COVID-19 are now well described. Evidence is emerging of serious longer-term complications occurring in the convalescent phase of the illness in a significant proportion of patients; particularly cardiovascular and pulmonary complications.
Patients have reported a range of longer-term symptoms associated with Long COVID that have significant impacts on their quality of life.
To date, there has been little work evaluating treatments in the convalescent phase of COVID-19. HEAL-COVID aims to evaluate the impact of treatments on longer-term morbidity, mortality, re-hospitalisation, symptom burden and quality of life associated with COVID-19.
The first two treatment arms are Apixaban and Atorvastatin, with further treatment arms to be added at the direction of the UK COVID-19 Therapeutic Advisory Panel (UKCTAP).
The TACTIC-E clinical trial is testing whether novel therapeutic agents or novel combinations of approved agents can prevent the development of severe symptoms in patients hospitalised with confirmed COVID-19.
The treatments currently being tested in TACTIC-E are:
- Ambrisentan in combination with Dapagliflozin
As in TACTIC-R, this study has been designed to swap out and add in alternative treatments, based on emerging data as the trial progresses. Click to read: TACTIC-E trial to test whether a simple microbe could be an effective treatment for COVID-19
This Cambridge-led, national trial will test whether two drugs that are already in use to treat other immune-related conditions can prevent the development of severe COVID-19 symptoms in patients admitted to hospital. Each of the drugs initially included in the trial, ravulizumab and baricitinib, target a different part of the over-active immune response thought to be the cause of severe COVID-19 disease. TACTIC-R is designed as a platform trial, so that further existing or new drugs that show promise for treating COVID-19 can easily be added to the trial. The chief investigator of TACTIC is Dr Frances Hall, Consultant Rheumatologist at Cambridge University Hospitals.
Creation of a cohort of COVID-19 patients to support research. Led by Professors Ken Smith and John Bradley, the NIHR COVID-19 BioResource allows patients admitted with suspected COVID-19 to participate in research by providing blood and other biological samples. Participants provide blood samples and nasal swabs, as well as consent to access their health records and completion of a short mental health questionnaire. Blood samples will undergo detailed analysis to assess immune responses to infection, in order to understand the determinants of disease course and severity. Combi ning these data with health records and genomic information will enable researchers to assess physical and mental health outcomes of infection.
- COPING study with NIHR BioResource: This study is being run by King’s College London and the NIHR BioResource. The COPING study will assess the impact of the novel coronavirus (COVID-19) pandemic on mental, physical and neurological health. Researchers are interested in how different factors associated with the virus are affecting the population. Members of the NIHR BioResource, GLAD Study and EDGI are being invited to take part in this study.If you have any questions or want further information on the study, you can contact the COPING Study team: COPINGstudy@kcl.ac.uk
Evaluation of a rapid test (diagnostic) for COVID-19 in clinical care. Led by Professor Ravindra Gupta and Dr Helen Lee, using the SAMBA-II machine. This technology was developed while Dr Lee was at Cambridge’s Department of Haematology and provides diagnostic information on the ward within 2 hours.
Using linkage of data from existing research cohorts such as NIHR BioResource to Public Health England and NHS-Digital in collaboration with HDRUK. Led by Professor John Danesh
COVID-19 Research for healthy volunteers and those with mild symptoms
The studies listed above are all recruiting patients who are hospitalised with suspected or confirmed COVID-19. If you have experienced mild COVID-19 symptoms or have not had the infection, there are still a variety of ways that you can support essential COVID-19 research. You can find out more about those opportunities here.
More information about COVID-19 research in Cambridge
Researchers from across Cambridge are collaborating closely to understand COVID-19 better and identify successful diagnostics and treatments. The links below highlight how we are working with our partners on the Biomedical Campus and throughout Cambridge on these essential studies:
- COVID-19 research studies from the University of Cambridge Department of Public Health and Primary Care
- Cambridge Fights COVID website outlining the collaborative COVID-19 effort across the Cambridge Biomedical Campus
- NIHR Applied Research Collaboration East of England COVID-19 Projects
Information for Research Teams
If you are a researcher in or around Cambridge who is looking for healthy volunteers for COVID-19 research or would like to involve our PPI panel in your research, please get in touch with the CUH R&D PPI and Communications team at firstname.lastname@example.org.
In order to feature in this list, the study needs to be registered through CUH R&D and be recruiting patients from in and around Cambridge. Cambridge based researchers are welcome to involve the CUH PPI panel at any stage of their research project or proposal.